Genzyme Board Recommends Shareholders Accept Sanofi-Aventis Revised Offer

Genzyme Board of Directors unanimously recommends that Genzyme shareholders accept the sanofi-aventis revised tender offer to purchase all outstanding shares of Genzyme common stock.

Genzyme Corporation announced that its Board of Directors unanimously recommends that Genzyme shareholders accept the sanofi-aventis revised tender offer to purchase all outstanding shares of Genzyme common stock for $74.00 and one contingent value right, per share.

The Board recommends that all Genzyme shareholders tender their shares into the revised tender offer.

Genzyme has filed with the Securities and Exchange Commission an amendment to its Solicitation/Recommendation Statement on Schedule 14D-9 that includes the basis for the Board’s recommendation along with other information relating to the tender offer.